These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

759 related items for PubMed ID: 24162815

  • 1. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
    Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park S, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Jänne PA, Doebele RC.
    Nat Med; 2013 Nov; 19(11):1469-1472. PubMed ID: 24162815
    [Abstract] [Full Text] [Related]

  • 2. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
    Chong CR, Bahcall M, Capelletti M, Kosaka T, Ercan D, Sim T, Sholl LM, Nishino M, Johnson BE, Gray NS, Jänne PA.
    Clin Cancer Res; 2017 Jan 01; 23(1):204-213. PubMed ID: 27370605
    [Abstract] [Full Text] [Related]

  • 3. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
    Xia H, Xue X, Ding H, Ou Q, Wu X, Nagasaka M, Shao YW, Hu X, Ou SI.
    Clin Lung Cancer; 2020 May 01; 21(3):247-254. PubMed ID: 31761448
    [Abstract] [Full Text] [Related]

  • 4. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.
    Créancier L, Vandenberghe I, Gomes B, Dejean C, Blanchet JC, Meilleroux J, Guimbaud R, Selves J, Kruczynski A.
    Cancer Lett; 2015 Aug 28; 365(1):107-11. PubMed ID: 26001971
    [Abstract] [Full Text] [Related]

  • 5. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.
    Park DY, Choi C, Shin E, Lee JH, Kwon CH, Jo HJ, Kim HR, Kim HS, Oh N, Lee JS, Park OK, Park E, Park J, Shin JY, Kim JI, Seo JS, Park HD, Park J.
    Oncotarget; 2016 Feb 16; 7(7):8399-412. PubMed ID: 26716414
    [Abstract] [Full Text] [Related]

  • 6. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
    Lee SJ, Li GG, Kim ST, Hong ME, Jang J, Yoon N, Ahn SM, Murphy D, Christiansen J, Wei G, Hornby Z, Lee DW, Park JO, Park YS, Lim HY, Hong SN, Kim SH, Kang WK, Park K, Park WY, Kim KM, Lee J.
    Oncotarget; 2015 Nov 17; 6(36):39028-35. PubMed ID: 26472021
    [Abstract] [Full Text] [Related]

  • 7. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population.
    Zhao R, Yao F, Xiang C, Zhao J, Shang Z, Guo L, Ding W, Ma S, Yu A, Shao J, Zhu L, Han Y.
    J Pathol Clin Res; 2021 Jul 17; 7(4):375-384. PubMed ID: 33768710
    [Abstract] [Full Text] [Related]

  • 8. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
    Lee YC, Chen JY, Huang CJ, Chen HS, Yang AH, Hang JF.
    Endocr Pathol; 2020 Dec 17; 31(4):348-358. PubMed ID: 32880785
    [Abstract] [Full Text] [Related]

  • 9. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT.
    J Thorac Oncol; 2015 Dec 17; 10(12):1670-4. PubMed ID: 26565381
    [Abstract] [Full Text] [Related]

  • 10. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS, Kenudson M, Zheng Z, Liebers M, Cha YJ, Hoang Ho Q, Onozato M, Phi Le L, Heist RS, Iafrate AJ.
    J Thorac Oncol; 2015 Aug 17; 10(8):1156-62. PubMed ID: 26200269
    [Abstract] [Full Text] [Related]

  • 11. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
    Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, Raddrizzani L, Palmeri L, Banfi P, Bonazzina E, Misale S, Marrapese G, Leone A, Alzani R, Luo D, Hornby Z, Lim J, Veronese S, Vanzulli A, Bardelli A, Martignoni M, Davite C, Galvani A, Isacchi A, Siena S.
    J Natl Cancer Inst; 2016 Jan 17; 108(1):. PubMed ID: 26563355
    [Abstract] [Full Text] [Related]

  • 12. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
    Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri F, Banfi P, Avanzi N, Saccardo MB, Alzani R, Bandiera T, Felder E, Donati D, Pesenti E, Sartore-Bianchi A, Gambacorta M, Pierotti MA, Siena S, Veronese S, Galvani A, Isacchi A.
    Mol Oncol; 2014 Dec 17; 8(8):1495-507. PubMed ID: 24962792
    [Abstract] [Full Text] [Related]

  • 13. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
    Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, Park KJ, Soslow RA, Oliva E, Iafrate AJ, Benayed R, Ladanyi M, Antonescu CR.
    Am J Surg Pathol; 2018 Jun 17; 42(6):791-798. PubMed ID: 29553955
    [Abstract] [Full Text] [Related]

  • 14. Oncogenic rearrangements of the NTRK1/NGF receptor.
    Pierotti MA, Greco A.
    Cancer Lett; 2006 Jan 28; 232(1):90-8. PubMed ID: 16242838
    [Abstract] [Full Text] [Related]

  • 15. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K.
    Cancer Sci; 2018 Oct 28; 109(10):3149-3158. PubMed ID: 30053332
    [Abstract] [Full Text] [Related]

  • 16. EPS15-NTRK1: a novel NTRK1 oncogenic fusion in patient with lung adenocarcinoma.
    Yang S, Li L, Chen D, Xiao M, Xian L.
    J Cancer Res Clin Oncol; 2020 Dec 28; 146(12):3389-3392. PubMed ID: 33037466
    [No Abstract] [Full Text] [Related]

  • 17. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
    Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, López-Rios F, Douillard JY, Andrè F, Reis-Filho JS.
    Ann Oncol; 2019 Sep 01; 30(9):1417-1427. PubMed ID: 31268127
    [Abstract] [Full Text] [Related]

  • 18. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH, Hong JH, Choi YL, Lee JA, Seo MK, Lee MS, An SB, Sung MJ, Cho NY, Kim SS, Shin YK, Kim S, Kang GH.
    J Pathol; 2021 Dec 01; 255(4):399-411. PubMed ID: 34402529
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ, Okada K, Oh-Hara T, Ogura H, Fujita N, Katayama R.
    Mol Cancer Ther; 2017 Oct 01; 16(10):2130-2143. PubMed ID: 28751539
    [Abstract] [Full Text] [Related]

  • 20. TRKA expression and NTRK1 gene copy number across solid tumours.
    Mauri G, Valtorta E, Cerea G, Amatu A, Schirru M, Marrapese G, Fiorillo V, Recchimuzzo P, Cavenago IS, Bonazzina EF, Motta V, Lauricella C, Veronese S, Tosi F, Maiolani M, Rospo G, Truini M, Bonoldi E, Christiansen J, Potts SJ, Siena S, Sartore-Bianchi A.
    J Clin Pathol; 2018 Oct 01; 71(10):926-931. PubMed ID: 29802225
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.